RELATED CONTENT
NEWS
- US FDA lawyers urge no 'do-over' for Avastin breast cancer indication
- California Blue Shield to no longer pay for Avastin in breast cancer
- FDA makes it official: AstraZeneca's Iressa, Sanofi's Oforta NDAs withdrawn
- Poor efficacy undermines Genentech metastatic breast cancer indication for Avastin
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

